Bispecific PD-L1 CTLA4 Dimer for Concurrent Immune Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current concurrent therapies involving separate intravenous doses of PD1/PD-L1 antibody and CTLA4 antibody for cancer treatment are inconvenient, painful, and have sub-optimal efficacy and safety issues, highlighting the need for new agents that can simultaneously target multiple pathways.
Innovation Solution
A dimer comprising two polypeptide chain monomers, each with an antibody Fc subunit, incorporating two or more immunoglobulin single variable domains (ISVDs) specific for PD-L1 and CTLA4, allowing for simultaneous targeting of these proteins.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If concurrent therapy using separate intravenous doses of PD1/PD-L1 antibody and CTLA4 antibody is used, then tumor-specific T-cell immunity is enhanced, but patient convenience deteriorates and treatment complexity increases
Solution Approach 1:
The patent combines two separate therapeutic antibodies (anti-PD-L1 and anti-CTLA4) into a single bispecific antibody molecule that can simultaneously bind both targets. This merging approach maintains the dual-immunomodulatory effect while eliminating the need for separate intravenous administrations, thereby improving patient convenience without compromising therapeutic efficacy
Solution Approach 2:
The bispecific antibody is designed with two distinct binding sites: one for PD-L1 and another for CTLA4. This multi-functional design allows a single agent to perform multiple therapeutic functions (blocking both PD-1/PD-L1 interaction and CTLA4-mediated inhibition) simultaneously, resolving the contradiction between enhanced immunity and treatment convenience
2Reliability
If concurrent therapy using separate intravenous doses of PD1/PD-L1 antibody and CTLA4 antibody is used, then tumor-specific T-cell immunity is enhanced, but manufacturing and characterization difficulty increases
Solution Approach 1:
By merging the functions of two separate antibodies into a single bispecific antibody molecule, the patent reduces the number of manufacturing processes from two separate antibody productions to one unified production process. This also simplifies characterization by eliminating the need to separately validate and monitor two distinct agents, thereby reducing manufacturing and characterization difficulty while maintaining dual-target efficacy
3Adaptability or versatility
If concurrent therapy using separate intravenous doses of PD1/PD-L1 antibody and CTLA4 antibody is used, then multiple targets are addressed, but treatment safety deteriorates due to sub-optimal efficacy and safety issues
Solution Approach 1:
The bispecific antibody is engineered to simultaneously target both PD-L1 and CTLA4 with optimized binding affinities, ensuring that both immunomodulatory pathways are effectively regulated by a single agent. This unified approach allows for better control of dosing and pharmacokinetics compared to concurrent therapy, thereby improving treatment safety while maintaining multi-target coverage
Data Source
AI summary
The present disclosure provides a dimer formed by two polypeptide chains, with each of the two polypeptide chains comprising an antibody Fc subunit, wherein the dimer comprises two or more immunoglobulin single variable domains (ISVDs), at least one of the ISVDs is specific for PD-L1, and at least one of the ISVDs is specific for CTLA4.